Alliance for Pandemic Preparedness

July 15, 2020

An MRNA Vaccine against SARS-CoV-2 — Preliminary Report



  • The candidate vaccine mRNA-1273 was shown to induce antibody and T-cell immune responses in all participants (n=45). 
  • Jackson et al. conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, to test the candidate vaccine mRNA-1273 encoding the stabilized prefusion of SARS-CoV-2 spike protein. Participants received two vaccinations, 28 days apart in three dose groups. 
  • After the first vaccination, antibody responses were higher among those who received the higher dose. After the second vaccination, the titers increased and all participants had serumneutralizing activity. No trial-limiting safety concerns were identified.  

Jackson et al. (July 14, 2020). An MRNA Vaccine against SARS-CoV-2 — Preliminary Report. New England Journal of Medicine.